Trial reportDrug design, development and therapy2026
The Effects of Remimazolam Tosylate on Postoperative Memory Function in Young and Middle-Aged Patients Undergoing Laparoscopic Surgery.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clarifying Baseline Cognitive Eligibility and Cross-Scale Follow-Up in a Randomized Trial of Remimazolam Tosylate for Laparoscopic Surgery [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This randomized controlled trial compared the effects of remimazolam tosylate versus propofol on postoperative memory function in young and middle-aged adults undergoing laparoscopic surgery. Patients and Methods: 228 patients were randomized to receive either remimazolam or propofol (n=114 each) for induction and maintenance of general anesthesia, guided by Bispectral Index (BIS). Memory and cognitive functions were assessed preoperatively and on postoperative days 1 and 3 using the Three-Word Recall Test (TRT), Memory and Executive Screening (MES), and Montreal Cognitive Assessment (MoCA), with a follow-up at one month via the Telephone Interview for Cognitive Status-modified (TICS-m). Serum levels of IL-6, S100β, and NfL were measured preoperatively, at 30 minutes, and 24 hours post-surgery. Perioperative parameters and adverse events were recorded. Results: The incidence of early postoperative memory decline on days 1 and 3 was significantly lower in the remimazolam group compared to the propofol group (P < 0.05). The remimazolam group also exhibited significantly lower postoperative levels of IL-6 and S100β, more stable hemodynamics, and a reduced incidence of hypotension and bradycardia (all P < 0.05). The incidence of postoperative cognitive dysfunction (POCD) did not differ significantly between groups. Multivariate analysis identified lower educational level, diabetes, propofol use, and longer anesthesia duration as independent risk factors for early postoperative memory decline. Conclusion: For young and middle-aged patients undergoing laparoscopic surgery, remimazolam reduces the incidence of early postoperative memory decline (within the first three days) and provides superior hemodynamic stability with a milder inflammatory response compared to propofol. However, no significant difference was observed in cognitive function at one month postoperatively, indicating that the benefits are primarily confined to the early recovery period.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.